HIF1A and acute myeloid leukemia: To gain a deeper understanding of the underlying mechanism and explore potential therapeutic avenues, we opted to treat these FLT3-ITD leukemic cells with a HIF-1α inhibitor, given previous reports indicating that HIF-1α drives pro-survival signaling pathways in AML (18, 19).